Capricor Therapeutics Debt to Equity Ratio 2010-2025 | CAPR
Current and historical debt to equity ratio values for Capricor Therapeutics (CAPR) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Capricor Therapeutics debt/equity for the three months ending March 31, 2025 was 0.00.
| Capricor Therapeutics Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-03-31 | $0.03B | $0.13B | 0.21 |
| 2024-12-31 | $0.03B | $0.15B | 0.17 |
| 2024-09-30 | $0.03B | $0.07B | 0.36 |
| 2024-06-30 | $0.03B | $0.01B | 2.33 |
| 2024-03-31 | $0.03B | $0.02B | 1.68 |
| 2023-12-31 | $0.04B | $0.02B | 1.60 |
| 2023-09-30 | $0.04B | $0.00B | -21.78 |
| 2023-06-30 | $0.04B | $0.00B | 15.85 |
| 2023-03-31 | $0.05B | $0.01B | 7.68 |
| 2022-12-31 | $0.04B | $0.01B | 3.25 |
| 2022-09-30 | $0.04B | $0.02B | 2.50 |
| 2022-06-30 | $0.04B | $0.02B | 2.10 |
| 2022-03-31 | $0.04B | $0.03B | 1.64 |
| 2021-12-31 | $0.01B | $0.03B | 0.32 |
| 2021-09-30 | $0.01B | $0.04B | 0.17 |
| 2021-06-30 | $0.01B | $0.03B | 0.20 |
| 2021-03-31 | $0.01B | $0.04B | 0.20 |
| 2020-12-31 | $0.01B | $0.03B | 0.23 |
| 2020-09-30 | $0.01B | $0.03B | 0.19 |
| 2020-06-30 | $0.01B | $0.03B | 0.17 |
| 2020-03-31 | $0.01B | $0.01B | 0.49 |
| 2019-12-31 | $0.00B | $0.01B | 0.63 |
| 2019-09-30 | $0.00B | $0.00B | 1.22 |
| 2019-06-30 | $0.01B | $0.00B | 2.09 |
| 2019-03-31 | $0.01B | $0.00B | 1.30 |
| 2018-12-31 | $0.01B | $0.01B | 1.00 |
| 2018-09-30 | $0.01B | $0.01B | 0.75 |
| 2018-06-30 | $0.01B | $0.01B | 0.49 |
| 2018-03-31 | $0.01B | $0.01B | 0.46 |
| 2017-12-31 | $0.01B | $0.01B | 0.45 |
| 2017-09-30 | $0.02B | $0.00B | -4.70 |
| 2017-06-30 | $0.02B | $-0.01B | -3.16 |
| 2017-03-31 | $0.02B | $-0.01B | -2.96 |
| 2016-12-31 | $0.02B | $0.00B | -5.68 |
| 2016-09-30 | $0.02B | $0.00B | 497.41 |
| 2016-06-30 | $0.02B | $-0.01B | -3.72 |
| 2016-03-31 | $0.02B | $0.00B | -16.69 |
| 2015-12-31 | $0.02B | $0.00B | -16.57 |
| 2015-09-30 | $0.02B | $0.00B | 9.33 |
| 2015-06-30 | $0.02B | $0.01B | 4.20 |
| 2015-03-31 | $0.02B | $0.01B | 2.75 |
| 2014-12-31 | $0.02B | $-0.01B | -3.18 |
| 2014-09-30 | $0.02B | $0.00B | -4.64 |
| 2014-06-30 | $0.02B | $0.00B | -6.98 |
| 2014-03-31 | $0.02B | $0.00B | -10.63 |
| 2013-12-31 | $0.01B | $0.00B | -11.35 |
| 2013-09-30 | $0.00B | $0.00B | -1.07 |
| 2013-06-30 | $0.00B | $0.00B | -1.24 |
| 2013-03-31 | $0.00B | $0.00B | -1.65 |
| 2012-12-31 | $0.00B | $0.01B | 0.11 |
| 2012-09-30 | $0.00B | $0.00B | 17.21 |
| 2012-06-30 | $0.00B | $0.00B | 0.84 |
| 2012-03-31 | $0.00B | $0.00B | 2.10 |
| 2011-12-31 | $0.00B | $0.00B | 0.65 |
| 2011-09-30 | $0.00B | $0.00B | 0.30 |
| 2011-06-30 | $0.00B | $0.00B | 0.13 |
| 2011-03-31 | $0.00B | $0.00B | 0.44 |
| 2010-12-31 | $0.00B | $0.00B | 0.41 |
| 2010-09-30 | $0.00B | $0.00B | 0.46 |
| 2010-06-30 | $0.00B | $0.01B | 0.24 |
| 2010-03-31 | $0.00B | $0.00B | 0.60 |
| 2009-12-31 | $0.00B | $0.00B | 0.21 |
| 2009-09-30 | $0.00B | $0.00B | 0.21 |
| 2009-06-30 | $0.00B | $0.00B | 0.24 |
| 2009-03-31 | $0.00B | $0.00B | 0.22 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.431B | $0.022B |
| Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $234.530B | 28.20 |
| Boston Scientific (BSX) | United States | $156.880B | 39.27 |
| Stryker (SYK) | United States | $150.466B | 31.46 |
| EssilorLuxottica (ESLOY) | France | $133.537B | 0.00 |
| Medtronic (MDT) | Ireland | $110.863B | 16.19 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.634B | 0.00 |
| Haleon (HLN) | United Kingdom | $48.687B | 27.69 |
| ResMed (RMD) | United States | $36.905B | 27.72 |
| GE HealthCare Technologies (GEHC) | United States | $33.485B | 15.90 |
| Agilent Technologies (A) | United States | $32.436B | 21.43 |
| Terumo (TRUMY) | Japan | $27.642B | 35.90 |
| Insulet (PODD) | United States | $22.854B | 89.71 |
| Koninklijke Philips (PHG) | Netherlands | $22.587B | 16.24 |
| Zimmer Biomet Holdings (ZBH) | United States | $19.181B | 12.32 |
| Baxter (BAX) | United States | $16.247B | 12.13 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.648B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $8.231B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.767B | 23.55 |
| Lantheus Holdings (LNTH) | United States | $5.621B | 14.18 |
| Prestige Consumer Healthcare (PBH) | United States | $4.402B | 19.67 |
| Perrigo (PRGO) | Ireland | $3.719B | 9.43 |
| Haemonetics (HAE) | United States | $3.532B | 15.39 |
| ICU Medical (ICUI) | United States | $3.480B | 25.66 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.097B | 25.73 |
| QuidelOrtho (QDEL) | United States | $2.263B | 15.56 |
| GN Store Nord (GNNDY) | Denmark | $2.097B | 17.37 |
| LeMaitre Vascular (LMAT) | United States | $1.915B | 42.81 |
| AtriCure (ATRC) | United States | $1.619B | 0.00 |
| Neogen (NEOG) | United States | $1.435B | 18.36 |
| Kestra Medical Technologies (KMTS) | United States | $1.264B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.217B | 12.36 |
| Green Thumb Industries (GTBIF) | United States | $1.182B | 26.59 |
| BioLife Solutions (BLFS) | United States | $1.121B | 0.00 |
| InMode (INMD) | Israel | $1.020B | 9.34 |
| Phibro Animal Health (PAHC) | United States | $0.973B | 12.44 |
| CeriBell (CBLL) | United States | $0.649B | 0.00 |
| Evolus (EOLS) | United States | $0.625B | 0.00 |
| Owens & Minor (OMI) | United States | $0.570B | 4.73 |
| Curaleaf Holdings (CURLF) | Canada | $0.553B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.535B | 0.00 |
| Valneva SE (VALN) | France | $0.524B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.498B | 0.00 |
| Surmodics (SRDX) | United States | $0.409B | 0.00 |
| SNDL (SNDL) | Canada | $0.355B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.335B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.325B | 11.94 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.321B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.305B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.288B | 51.30 |
| Sanara MedTech (SMTI) | United States | $0.280B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.276B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.267B | 22.53 |
| Cerus (CERS) | United States | $0.254B | 0.00 |
| ZimVie (ZIMV) | United States | $0.251B | 11.41 |
| Verano Holdings (VRNOF) | United States | $0.235B | 0.00 |
| Biote (BTMD) | United States | $0.224B | 6.31 |
| High Tide (HITI) | Canada | $0.191B | 0.00 |
| Omeros (OMER) | United States | $0.187B | 0.00 |
| Brainsway (BWAY) | Israel | $0.187B | 49.55 |
| Quanterix (QTRX) | United States | $0.186B | 0.00 |
| Organigram Global (OGI) | Canada | $0.182B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.182B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.181B | 14.58 |
| TriSalus Life Sciences (TLSI) | United States | $0.166B | 0.00 |
| Exagen (XGN) | United States | $0.128B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.128B | 15.77 |
| Jin Medical (ZJYL) | China | $0.125B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.113B | 0.00 |
| Agape ATP (ATPC) | $0.103B | 0.00 | |
| MacroGenics (MGNX) | United States | $0.100B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.088B | 0.00 |
| Fonar (FONR) | United States | $0.080B | 10.32 |
| Veru (VERU) | United States | $0.076B | 0.00 |
| Zynex (ZYXI) | United States | $0.075B | 0.00 |
| InterCure (INCR) | Israel | $0.069B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.063B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.061B | 0.00 |
| United Health Products (UEEC) | United States | $0.061B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.056B | 0.00 |
| Apyx Medical (APYX) | United States | $0.054B | 0.00 |
| ImmuCell (ICCC) | United States | $0.048B | 0.00 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| United-Guardian (UG) | United States | $0.039B | 13.35 |
| Rockwell Medical (RMTI) | United States | $0.035B | 0.00 |
| Safety Shot (SHOT) | United States | $0.031B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.024B | 0.00 |
| Nephros (NEPH) | United States | $0.023B | 30.86 |
| INLIF (INLF) | $0.018B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.015B | 0.00 |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.010B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |